Abstract
Introduction: Autism spectrum disorder, major depressive disorder,
anxiety disorders, post-traumatic stress disorder, schizophrenia,
insomnia, and disorders related to psychotropic substances are common
diseases worldwide and in Colombia. The pharmacological treatments
available for the management of mental disorders are effective, although
adverse reactions sometimes limit their use; additionally, some patients
do not have an adequate response to them, which generates the need to
develop new effective and safe drugs. Methodology: A Delphi consensus
was developed in real-time, with a panel of seven psychiatric
specialists and a group of developer epidemiologists; a systematic
search was carried out in 3 specialized databases and contributed
articles. By the panel of experts participating in the consensus, two
questionnaires were applied for consideration by the group of experts,
anonymously and on an online platform with the Likert scale. Results:
Recommendations were established based on the available evidence and the
experience provided by the experts. Conclusions: There is biological
plausibility in clinical and preclinical studies that suggest the
effectiveness of the use of pure pharmaceutical-grade CBD, as adjunctive
therapy, for the control of symptoms associated with mental disorders
such as schizophrenia and disorders related to the abuse of psychotropic
substances. However, more rigorous clinical trials are required to make
more precise recommendations on CBD to treat other mental disorders.
Additionally, pure pharmaceutical-grade CBD is considered a safe
treatment.